Bioengineering
New bioengineering study results reported from Y. Matsumoto et al
Published in Drug Law Weekly, August 21st, 2007
"Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor (VEGF), has been given via intravitreal injection as an off-label therapy for both neovascular age-related macular degeneration and for macular edema secondary to retinal vascular disease. The authors describe three patients with macular edema secondary to retinal venous occlusion whose edema initially responded to intravitreal bevacizumab but subsequently recurred in excess of that observed before treatment," investigators in the United States report.
"This is a retrospective case series of three patients with macular edema secondary to retinal vein occlusion treated with intravitreal...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-08-21)
More Articles from Drug Law Weekly
- Bioengineering
Point Therapeutics Reports Second Quarter 2007 Financial Results - Biopharmaceuticals
GTC Biotherapeutics Reports Second Quarter 2007 Financial Results - Biotechnology Business
Biovail Enters Into License and Development Agreement - Biotechnology Business
DUSA Pharmaceuticals Reports Second Quarter 2007 Corporate Highlights and Financial Results - Chemicals
Abraxis BioScience Acquires from the Buck Institute Exclusive Worldwide Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates - Clinical Trial Research
Cutera Reports Second Quarter 2007 Results - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
